Molecular Bioprocessing as a New Paradigm for Drug Discovery
- Type: Archived Webinar
The drug discovery process is expensive and often inefficient. With the emergence of genomic and proteomic information, the growth of critical molecular targets is rapid. Nevertheless, the development of active, selective, and safe drug candidates (small molecule or biopharmaceutical) has not kept pace with such advances. For small molecules, a core problem is the lack of high-throughput and accurate methodologies for ADME/Tox, which forces comprehensive toxicology studies to be performed only on later stage lead compounds and preclinical candidates. For biopharmaceuticals, the ability to accurately reproduce the human protein with correct posttranslational modification is limited by lack of knowledge of cellular machinery and then the efficient scale up of protein production and purification. Professor Dordick will detail his research in the design and optimization of high-throughput, microscale discovery and development platforms and the emergence of using bioprocessing strategies at early stages of drug discovery.
Jonathan S. Dordick is the Howard P. Isermann Professor of Chemical and Biological Engineering at VP President for Research. Prof. Dordick received his B.A. in Biochemistry and Chemistry from Brandeis University and his Ph.D. in Biochemical Engineering from MIT. He has held chemical engineering faculty appointments at the University of Iowa, where he also served as the Associate Director of the Center for Biocatalysis and Bioprocessing, and RPI (1998-present) where he also holds joint appointments in the departments of Biomedical Engineering, Materials Science and Engineering, and Biology...Read more
Do you already own this?
Log In for instructions on accessing this content.
|AIChE Member Credits||1|
|AIChE Undergraduate Student Members||Free|
|AIChE Graduate Student Members||Free|